GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bruker Corp (NAS:BRKR) » Definitions » Debt-to-EBITDA

Bruker (Bruker) Debt-to-EBITDA : 1.22 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Bruker Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bruker's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $145 Mil. Bruker's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,235 Mil. Bruker's annualized EBITDA for the quarter that ended in Dec. 2023 was $1,130 Mil. Bruker's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.22.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bruker's Debt-to-EBITDA or its related term are showing as below:

BRKR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.06   Med: 2.04   Max: 2.85
Current: 2.04

During the past 13 years, the highest Debt-to-EBITDA Ratio of Bruker was 2.85. The lowest was 1.06. And the median was 2.04.

BRKR's Debt-to-EBITDA is ranked worse than
62.24% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.24 vs BRKR: 2.04

Bruker Debt-to-EBITDA Historical Data

The historical data trend for Bruker's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bruker Debt-to-EBITDA Chart

Bruker Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.37 2.85 2.81 2.45 2.04

Bruker Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.12 2.26 2.90 2.04 1.22

Competitive Comparison of Bruker's Debt-to-EBITDA

For the Medical Devices subindustry, Bruker's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bruker's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bruker's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bruker's Debt-to-EBITDA falls into.



Bruker Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bruker's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(144.5 + 1235.1) / 675.5
=2.04

Bruker's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(144.5 + 1235.1) / 1130.4
=1.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Bruker  (NAS:BRKR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Bruker Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bruker's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bruker (Bruker) Business Description

Traded in Other Exchanges
Address
40 Manning Road, Billerica, MA, USA, 01821
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.
Executives
Frank H Laukien director, 10 percent owner, officer: CEO, President C/O BRUKER DALTONICS, 40 MANNING ROAD, BILLERICA MA 01821
Marc A Kastner director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Cynthia M Friend director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Richard A Packer director 9 KENDALL DRIVE, WESTBOROUGH MA 01581
Philip Ma director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Mark Munch officer: Pres. Bruker Nano Inc. BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Juergen Srega officer: Group President Bruker CALID BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Burkhard Prause officer: Pres. & CEO, Bruker EST BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Bonnie H Anderson director 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Martin Gilles Gerard Jean director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Falko Busse officer: President, BioSpin Group 40 MANNING ROAD, BILLERICA MA 01821
Gerald N Herman officer: Vice President, Corp Contr. 55 EXECUTIVE DRIVE, HUDSON NH 03051
Ingen Chris Van director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Richard Kniss director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Adelene Q Perkins director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139